QoL) and associated disease
burden and work productivity loss.3-6 In 2014, the annualized US payer disease burden for venous leg ulcers was
estimated to be around US$15 billion, and the overall
treatment cost for varicose veins is projected to reach
US$8 trillion by 2021.2,4,7,8 The disease prevalence is also
expected to increase owing to the obesity pandemic
